Close

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. META
3. ENPH
4. TXN
5. BA
6. SPOT
7. IBM
8. V
9. HCP
10. KMB


Go back to Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 51.74 --0 (-0%)
Previous Close $51.74    52 Week High $118.49 
Open $51.74    52 Week Low $55.00 
Day High $51.74    P/E N/A 
Day Low $51.74    EPS $-0.56 
Volume 157